Former Dendreon CEO, Amgen scientists team up on new immunotherapy startup
Former Dendreon Corp. CEO Mitchell Gold isn't leaving the biotech world anytime soon despite that company's recent bankruptcy and sale to Quebec-based Valeant Pharmaceuticals.
Instead, he decided to form a new immunotherapy biotech company that will target cancer and autoimmune diseases. He's doing it with the help of scientists from the departing biotech Amgen, which will shutter its operations in Washington state by the end of 2015.
Alpine Immune Sciences Inc., founded in January, is still in…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Annie Zak Source Type: news
More News: American Health | Autoimmune Disease | Biotechnology | Cancer | Cancer & Oncology | Health | Health Management